AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

Roche is the recipient of the new approval, getting the go-ahead from the US regulator for its PATHWAY HER2 (4B5) test to ...

Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...

A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super ...

but could possibly widen to breast cancer drug Enhertu as well. The firm is continuing to co-operate with Chinese authorities. AstraZeneca appointed a new president for its China business late ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

AstraZeneca PLC (LON:AZN:LN) (NASDAQ: AZN), a pharmaceutical giant with a market capitalization of $224.5 billion, received a new Overweight rating from Morgan Stanley (NYSE:MS), accompanied by a ...

AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising ...

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...

AstraZeneca is expecting Phase III trial data for seven new medicines in 2025, its CEO said as he confirmed the company’s ...